Health Ministry proposes central oversight for antimicrobials, bulk drug licensing reform

Share:
Audio Loading voice…
Health Ministry proposes central oversight for antimicrobials, bulk drug licensing reform

Synopsis

India's Health Ministry has proposed two sweeping pharmaceutical reforms in one move: bringing antimicrobials under central licensing oversight to combat resistance risks, and creating a dedicated bulk drug licence framework to close a long-standing supply chain accountability gap. Both proposals are open for public comment before finalisation.

Key Takeaways

The Health Ministry on 19 November 2026 proposed amending the New Drugs and Clinical Trials Rules, 2019 to place antimicrobials under Central Licensing Authority (CLA) oversight.
Manufacturers would need CLA permission before applying to a State Licensing Authority for a manufacturing licence.
The move is aimed at ensuring bioavailability, bioequivalence, and stability studies are conducted — currently absent in state-level approvals.
A separate amendment to the Drugs Rules, 1945 would create a dedicated licence for wholesale bulk drug sales, distinct from formulation licences.
Bulk drug sales would require supervision by a competent person , with NDPS-covered substances specifically tracked.
Both draft notifications are open for public objections and suggestions before finalisation.

India's Health Ministry on Thursday, 19 November 2026, proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, that would place antimicrobial products under Central Licensing Authority (CLA) oversight — a move aimed at tightening quality controls and curbing the spread of antimicrobial resistance (AMR). A separate proposal to reform bulk drug licensing was announced alongside, targeting gaps in India's pharmaceutical supply chain.

Why Central Oversight for Antimicrobials

The ministry cited concerns that manufacturing licences for antimicrobial products were being granted by state authorities without adequate regulatory scrutiny — specifically, without the bioavailability, bioequivalence, and stability studies typically required for new drugs. According to an official statement, the absence of these assessments risks compromising the quality, safety, and efficacy of antimicrobials.

The statement warned that substandard or ineffective antimicrobials can accelerate the development and spread of antimicrobial resistance, a recognised threat to patient safety. India is among the world's largest consumers and producers of antibiotics, making robust regulatory oversight a matter of public health urgency.

What the Proposed Amendment Would Change

Under the proposed framework, manufacturers would be required to secure permission from the Central Licensing Authority before applying for a manufacturing licence from the relevant State Licensing Authority (SLA). This two-step clearance would effectively bring antimicrobials within the same regulatory bracket as new drugs under the 2019 Rules.

'Accordingly, manufacturers would be required to obtain permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the concerned State Licensing Authority (SLA). This is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products,' the ministry's statement read.

The draft notification has been published to invite objections and suggestions from stakeholders and members of the public before the amendment is considered for finalisation by the Central Government.

Bulk Drug Licensing: Closing a Supply Chain Gap

In a parallel proposal, the ministry has moved to amend the Drugs Rules, 1945, to introduce a separate application form and licence form for the wholesale sale of bulk drugs — covering both active and inactive bulk substances. At present, a single common licence covers wholesale sales of both formulations and bulk drugs, a conflation the ministry now considers insufficient for effective oversight.

The new dedicated licensing framework would require wholesalers to declare the categories of bulk drugs they handle, including those covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Critically, the sale of bulk drugs would be conducted under the personal supervision of a competent person, strengthening accountability across the distribution chain.

Significance and What Comes Next

Together, these two proposals represent a meaningful tightening of India's pharmaceutical regulatory architecture at a time when the country faces pressure — both domestically and from international partners — to demonstrate higher standards in drug manufacturing. Notably, India's pharmaceutical sector has faced recurring scrutiny over quality lapses in recent years, and the AMR threat is increasingly a global diplomatic priority.

Stakeholders and citizens have an opportunity to submit objections or suggestions before the amendments are finalised. The timeline for finalisation has not been specified, but the dual notification signals the ministry's intent to move on both fronts simultaneously. How quickly the Central Government converts these proposals into enforceable rules will be watched closely by industry and public health advocates alike.

Point of View

Not the notifications themselves. India's AMR burden is among the heaviest globally, and reform on paper means little if the Central Licensing Authority lacks the capacity — or the political will — to actually scrutinise every application it now receives.
NationPress
19 Nov 2026

Frequently Asked Questions

Why is the Health Ministry proposing to bring antimicrobials under central oversight?
The ministry found that manufacturing licences for antimicrobials were being granted by state authorities without adequate scrutiny — specifically, without bioavailability, bioequivalence, and stability studies. Substandard antimicrobials can accelerate antimicrobial resistance, posing risks to patient safety.
What will change for antimicrobial manufacturers under the proposed amendment?
Manufacturers will need to obtain prior permission from the Central Licensing Authority (CLA) before applying to a State Licensing Authority for a manufacturing licence. This brings antimicrobials within the same regulatory framework as new drugs under the New Drugs and Clinical Trials Rules, 2019.
What is the proposed reform to bulk drug licensing?
The ministry has proposed amending the Drugs Rules, 1945, to create a separate application form and licence specifically for the wholesale sale of bulk drugs, distinct from the existing combined licence for formulations and bulk substances. The new licence will also cover NDPS-scheduled bulk substances and require oversight by a competent person.
How can stakeholders participate before these amendments are finalised?
The draft notifications have been published to invite objections and suggestions from industry stakeholders and the general public. Submissions can be made before the Central Government considers the amendments for finalisation; a specific deadline was not stated in the ministry's announcement.
How does antimicrobial resistance connect to these regulatory changes?
Antimicrobial resistance (AMR) develops when substandard or ineffective medicines fail to fully eliminate pathogens, allowing resistant strains to survive and spread. By mandating rigorous quality studies before manufacture, the proposed central oversight aims to reduce the circulation of low-quality antimicrobials that contribute to AMR.
Nation Press
The Trail

Connected Dots

Tracing the thread behind this story — newest first.

8 Dots
  1. Latest 1 month ago
  2. 4 months ago
  3. 4 months ago
  4. 11 months ago
  5. 1 year ago
  6. 1 year ago
  7. 1 year ago
  8. 1 year ago
Google Prefer NP
On Google